New developments in osteoarthritis pharmacological therapies

Area of Science:

• Rheumatology
• Pharmacology
• Osteoarthritis Research

Background:

• Osteoarthritis (OA) is a prevalent, painful joint disease with complex causes and few effective treatments.
• Current therapeutic strategies involve repurposing drugs, modifying existing OA treatments, and developing new agents.

Purpose of the Study:

• To review the current landscape of osteoarthritis therapeutics.
• To evaluate the efficacy of various pharmacological approaches for managing OA symptoms and structural progression.

Main Methods:

• Review of clinical trial data for repurposed drugs (HCQ, MTX), biologics (anti-IL-6, anti-GM-CSF), and novel targets.
• Analysis of evidence for therapies targeting the peripheral nociceptive pathway (nerve growth factor, capsaicin, TRK-A inhibitors).

Main Results:

• Hydroxychloroquine (HCQ) and low-dose methotrexate (MTX) did not improve hand OA pain or structural progression.
• Anti-IL-6 and anti-GM-CSF therapies were ineffective for hand OA symptoms.
• Interleukin-1 (IL-1) remains a potential target for large-joint OA.
• Nerve growth factor monoclonal antibodies (mAbs) and intra-articular (IA) capsaicin showed efficacy in targeting nociceptive pathways.
• Tropomyosin receptor kinase A (TRK-A) inhibitors are in early development.

Conclusions:

• Current pharmacological options for OA are limited, with several repurposed and biologic agents showing minimal benefit.
• Targeting the peripheral nociceptive pathway and IL-1 presents promising avenues for future OA treatment development.
• More research is needed to confirm structural modification benefits and synchronous symptom relief for OA therapies.